Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial (Q34415030)

From Wikidata

Revision as of 13:33, 29 September 2024 by Egon Willighagen (talk | contribs) (‎Added reference to claim: main subject (P921): human papilloma virus (Q69999790), batch #238018)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

phase II clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

human papilloma virus

1 reference

object named as

human papillomavirus

29 September 2024

based on heuristic

inferred from title

Finn Egil Skjeldestad

11

object named as

Finn Egil Skjeldestad

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Cosette M Wheeler

7

object named as

Cosette M Wheeler

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

25

object named as

Kathrin U Jansen

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

8

object named as

Laura A Koutsky

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Luisa L Villa

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ronaldo L R Costa

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Carlos A Petta

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Rosires P Andrade

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Kevin A Ault

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Anna R Giuliano

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Christian Malm

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Matti Lehtinen

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sven-Eric Olsson

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Margareta Steinwall

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Darron R Brown

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Robert J Kurman

15

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Brigitte M Ronnett

16

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Mark H Stoler

17

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Alex Ferenczy

18

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Diane M Harper

19

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gretchen M Tamms

20

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jimmy Yu

21

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lisa Lupinacci

22

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Radha Railkar

23

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Frank J Taddeo

24

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Mark T Esser

26

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Heather L Sings

27

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Alfred J Saah

28

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Eliav Barr

29

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

271-278

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The cervical cancer epidemic that screening has prevented in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment for cervical intraepithelial neoplasia and risk of preterm delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification of papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The 2001 Bethesda System: terminology for reporting results of cervical cytology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The health care costs of cervical human papillomavirus--related disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sexual behaviour in Britain: early heterosexual experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970101-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(05)70101-7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34415030&oldid=2254296174"